世界最新医学信息文摘（电子版）
世界最新醫學信息文摘（電子版）
세계최신의학신식문적（전자판）
World Latest Medicine Information
2013年
6期
39-41
,共3页
艾塞那肽%百泌达%肠促胰素%胰高血糖素样肽%利拉鲁肽
艾塞那肽%百泌達%腸促胰素%胰高血糖素樣肽%利拉魯肽
애새나태%백비체%장촉이소%이고혈당소양태%리랍로태
exenatide%byetta%Glucagon like peptide-1%GLP-1 receptor agonists%liraglutide
目的比较 GLP-1受体激动剂与胰岛素治疗2型糖尿病的疗效及安全性。方法计算机检索 Springer、PubMed、Embase、CNKI 等数据库并手工检索相关文献。评价符合纳入标准的文献，对文献中的数据进行 meta 分析。结果GLP-1受体激动剂在控制 HbA1c 方面与胰岛素无明显差别，加权均数差=0.05，95%CI（-0.07,0.17)；在减轻体重方面优于胰岛素，加权均数差=4.55,95%CI (3.97,5.14)；在低血糖发生率方面优于胰岛素组，比值比=0.43295%CI (0.338,0.551)。结论 GLP-1受体激动剂是较胰岛素更有前景的治疗手段。
目的比較 GLP-1受體激動劑與胰島素治療2型糖尿病的療效及安全性。方法計算機檢索 Springer、PubMed、Embase、CNKI 等數據庫併手工檢索相關文獻。評價符閤納入標準的文獻，對文獻中的數據進行 meta 分析。結果GLP-1受體激動劑在控製 HbA1c 方麵與胰島素無明顯差彆，加權均數差=0.05，95%CI（-0.07,0.17)；在減輕體重方麵優于胰島素，加權均數差=4.55,95%CI (3.97,5.14)；在低血糖髮生率方麵優于胰島素組，比值比=0.43295%CI (0.338,0.551)。結論 GLP-1受體激動劑是較胰島素更有前景的治療手段。
목적비교 GLP-1수체격동제여이도소치료2형당뇨병적료효급안전성。방법계산궤검색 Springer、PubMed、Embase、CNKI 등수거고병수공검색상관문헌。평개부합납입표준적문헌，대문헌중적수거진행 meta 분석。결과GLP-1수체격동제재공제 HbA1c 방면여이도소무명현차별，가권균수차=0.05，95%CI（-0.07,0.17)；재감경체중방면우우이도소，가권균수차=4.55,95%CI (3.97,5.14)；재저혈당발생솔방면우우이도소조，비치비=0.43295%CI (0.338,0.551)。결론 GLP-1수체격동제시교이도소경유전경적치료수단。
Objective To assess the efficacy and safety of GLP-1 receptor agonist on the treatment of T2DM. Methods:To search randomized controlled trials from Springer, Pubmed, Embase, CNKI and to evaluate the quality of RCTs which are included on the basis of criteria . Meta analysis was conducted by the software Stata 12.0. Results : Meta analysis indicated that :GLP-1 receptor agonist was not inferior than insulin in lowering hemoglobin A1C. It was more effective than insulin in lowering weight and reducing the risk of hypoglycemia. Conclusion: GLP-1 receptor agonist was an effective and safe treatment for T2DM.
